Fig. 1.

Low UBR5 expression negatively associates with tumor stage and sunitinib resistance of ccRCC. a The expression of UBR5 in human ccRCC tissues (n = 533) and normal renal tissues (n = 72) from TCGA datasets was compared. b The expression of UBR5 was analyzed the same way as described above between tumor tissues (n = 72) and paired normal tissues (n = 72) in human ccRCC from TCGA datasets. c Real-time PCR was performed to assess the mRNA expression of UBR5 in tumor samples and their paired adjacent renal tissues from ccRCC patients (n = 60). d Western blot analysis was performed to measure the protein expression of UBR5 in ccRCC specimens and their matched adjacent renal tissues (n = 16). e Representative images of hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) staining for UBR5 in ccRCC tissues and the adjacent tissues of tissue microarrays are presented (n = 310; scale bar = 20 μm). f Representative images of H&E and IHC staining for UBR5 in ccRCC tissues with different TNM stages are shown (scale bar = 20 μm). g–h Western blot (g) or Real-time PCR (h) was performed to analyze the protein expression of UBR5 in a normal cell line (HK-2), local and metastatic ccRCC cell lines. i–j Western blot (i) or real-time PCR (j) was applied to detect the expression of UBR5 in 786-O-SR and 769-P-SR cells. All p values are defined as: *p < 0.05; **p < 0.01 and ***p < 0.001 (SR: sunitinib-resistant)